Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - BIOJECT MEDICAL TECHNOLOGIES INC | d33599dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 27, 2015
BIOJECT MEDICAL TECHNOLOGIES INC.
(Exact name of registrant as specified in its charter)
Commission File Number: 0-15360
| Oregon | 93-1099680 | |
| (State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
| 7180 SW Sandburg St., Ste. 100 Tigard, Oregon |
97223 | |
| (Address of principal executive offices) | (Zip Code) | |
| Registrant’s telephone number, including area code: (503) 692-8001 | ||
| Former name or former address if changed since last report: | ||
| No Change | ||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 2.02 Results of Operations and Financial Condition
On November 27, 2015, Bioject Medical Technologies Inc. (“Bioject”) issued a press release announcing its unaudited financial results for the third quarter ended September 30, 2015. The press release includes cautionary statements identifying important factors that could cause actual results to differ materially from those anticipated. The press release issued November 27, 2015 is furnished herewith as Exhibit No. 99.1 to this Report, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
Item 9.01 Financial Statements and Exhibits
| (d) | Exhibits |
| 99.1 | Press release issued by Bioject Medical Technologies Inc. dated November 27, 2015. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Date: November 27, 2015 | BIOJECT MEDICAL TECHNOLOGIES INC. (Registrant) | |||
| /s/ Tony K. Chow | ||||
| Tony K. Chow | ||||
| Chief Executive Officer, President and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer) | ||||